GRAPH2EM2503 - CME/CMLE - Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing

Course Description

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing

Activity Description:

This case-based activity is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in applying practice-changing updates regarding HER2-low and HER2-ultralow advanced breast cancer. Through three case-based microlearning activities learners will answer questions designed to help them carefully consider the nuances of HER2-low and HER2-ultralow breast cancer diagnosis. This is the third of the three activities and focuses on reproducibility of testing and clinical significance of HER2-low and HER2-ultralow.

Course topics include:

Interobserver variability in HER2 IHC scoring

Clinical significance of HER2-low and HER2-ultralow

Target Audience

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.

Faculty/Authors

Aysegul Sahin
Professor, Department of Pathology, Division of Pathology/Lab Medicine,The University of Texas MD Anderson Cancer Center, Houston, TX

Physician Competencies: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement

Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.

Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided online. 

Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Content and click the first module of the course.
Complete the Demographic Survey.
Complete the Pre-Test.
Review the Educational Activity.
Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures

Technical Considerations

Release Dates: 3/17/2025
Review Date:
Expiration Date: 3/17/2028

Course Objectives

Upon completion of this activity, you will be able to:

Discuss the interobserver variability in HER2 IHC scoring and its impact on treatment decisions

Describe the clinical significance of low and ultra-low HER2 expression in breast cancer

Explain the implications of HER2 reassessment in recurrent disease

Summary


Availability:	On-Demand


Credit Offered:	0.25 CME/CMLE Credit